Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Yasmeen Abouelhassan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, Microbial Sensitivity Tests, Anti-Bacterial Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: FDA HHS, Food and Drug Administration.
Abstract (Originalsprache)
Background
Sulbactam dosing for Acinetobacter baumannii infections has not been standardized due to limited available pharmacokinetics/pharmacodynamics (PK/PD) data. Herein, we report a comprehensive PK/PD analysis of ampicillin-sulbactam against A. baumannii pneumonia.
Methods
Twenty-one A. baumannii clinical isolates were tested in the neutropenic murine pneumonia model. For dose-ranging studies, groups of mice were administered escalating doses of ampicillin-sulbactam. Changes in log10cfu/lungs relative to 0 h were assessed. Dose-fractionation studies were performed. Estimates of the percentage of of time during which the unbound plasma sulbactam concentrations exceeded the MIC (%fT > MIC) required for different efficacy endpoints were calculated. The probabilities of target attainment (PTA) for the 1-log kill plasma targets were estimated following clinically utilized sulbactam regimens.
Results
Dose-fractionation studies demonstrated time-dependent kill. Isolates resistant to both sulbactam and meropenem required three times the exposures to achieve 1-log kill; median [IQR] %fT > MIC of 60.37% [51.6–66.8] compared with other phenotypes (21.17 [16.0–32.9] %fT > MIC). Sulbactam standard dose (1 g q6h, 0.5 h infusion) provided >90% PTA up to MIC of 4 mg/L. Sulbactam 3 g q8h, 4 h inf provided greater PTA for isolates with sulbactam-intermediate susceptibility (8 mg/L, 100% versus 86% following the standard dose). Despite the higher exposure following 3 g q8h, 4 h inf, PTA was ≤57% among sulbactam-resistant/meropenem-resistant isolates.
Conclusion
Sulbactam standard dose is a valuable regimen across sulbactam-susceptible isolates while the high-dose extended-infusion provides additional benefit against sulbactam-intermediate isolates. Given that most of the sulbactam-resistant A. baumannii isolates are meropenem-resistant, high-dose prolonged-infusion regimens are not expected to be effective as monotherapy against infections due to these isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
ORCID-Profile: Joseph L Kuti, David P Nicolau, Kamilia Abdelraouf
Förderung
- FDA HHS
- Food and Drug Administration
Zitieren
APA
Abouelhassan, Y., Kuti, J. L., Nicolau, D. P., & Abdelraouf, K. (2024). Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae218
Vancouver
Abouelhassan Y, Kuti JL, Nicolau DP, Abdelraouf K. Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae218
BibTeX
@article{Abouelhassan2024,
author = {Abouelhassan, Yasmeen and Kuti, Joseph L and Nicolau, David P and Abdelraouf, Kamilia},
title = {Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae218}
}
EUVIMED